GlobeNewswire Inc | Feb 22, 2021 04:01PM EST

February 22, 2021

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the Company or Fate Therapeutics)(NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company will present at the upcoming 10thAnnual SVB Leerink Healthcare Conference on Thursday, February 25, 2021, at 5:00 p.m. EST.

The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website atwww.fatetherapeutics.com. The archived webcast will be available on the Company's website shortly after the event.

AboutFate Therapeutics, Inc.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Companys immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Companys immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.

Contact:Christina TartagliaStern Investor Relations, Inc.212.362.1200christina@sternir.com